Target Information

Target General Infomation
Target ID
T07403
Target Name
Integrin alpha-4/beta-7
Target Type
Successful
Disease Crohn's disease [ICD9: 555; ICD10: K50]
Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51]
Multiple scierosis [ICD9: 340; ICD10: G35]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
BioChemical Class
Integrin
UniProt ID
P13612||P26010
Drugs and Mode of Action
Drug(s) MLN0002 Drug Info Approved Crohn's disease [533123], [542460], [551871]
TRK-170 Drug Info Phase 2 Inflammatory bowel disease [523458]
R1295 Drug Info Discontinued in Phase 1 Rheumatoid arthritis [536651]
TR-14035 Drug Info Discontinued in Phase 1 Multiple scierosis [547053]
Modulator MLN0002 Drug Info [533123]
R1295 Drug Info
TR-14035 Drug Info
TRK-170 Drug Info [1572591]
References
Ref 523458ClinicalTrials.gov (NCT01345799) A Study of TRK-170 for the Treatment of Crohn's Disease. U.S. National Institutes of Health.
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
Ref 536651Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
Ref 542460(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7437).
Ref 547053Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012563)
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.